{"id":"W4386244466","doi":"10.1200/jco.23.00558","title":"Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory <i>BRAF</i> V600–Mutant Pediatric High-Grade Glioma","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Brain Tumour Charity","keywords":"Trametinib; Dabrafenib; Medicine; Internal medicine; Oncology; Refractory (planetary science); Adverse effect; Discontinuation; Phases of clinical research; Rash; Clinical trial; Cancer; Vemurafenib; MAPK/ERK pathway; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001061812,0.00127422,0.001595472,0.0002994944,0.0002472633,0.0006540004,0.0005422821,0.0006206483,0.001929906],"category_scores_gemma":[0.0004946426,0.0003712408,0.0009065455,0.0002813471,0.0005126787,0.0004236266,0.0002139875,0.002089211,0.0004513911],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007753319,"about_ca_system_score_gemma":0.001247152,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001113665,"about_ca_topic_score_gemma":0.003356076,"domain_scores_codex":[0.9996995,0.0001631791,0.00001599389,0.00004137989,0.00002315897,0.0000569328],"domain_scores_gemma":[0.9996006,0.00004862209,0.00008966506,0.00002367291,0.00002019925,0.0002173043],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7641059,0.03192672,0.01425996,0.001343828,0.002250157,0.0007973593,0.000385028,0.003853465,0.04344537,0.0005306237,0.006348251,0.1307533],"study_design_scores_gemma":[0.681311,0.2917605,0.01658998,0.00005700366,0.000445379,0.0007209472,0.00007618831,0.001911744,0.003840143,0.0002073641,0.003053789,0.00002582913],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925533,0.002442408,0.000440297,0.0003413063,0.0001027388,0.001699278,0.0008543904,0.00008527017,0.001481032],"genre_scores_gemma":[0.9922275,0.001821545,0.00109969,0.0004803379,0.0001012742,0.00127622,0.001655814,0.00001763069,0.001320052],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001929906,"threshold_uncertainty_score":0.006456196,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1148913430030825,"score_gpt":0.4559964426832014,"score_spread":0.3411050996801189,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}